Prognostic significance of apoptotic cell death in bladder cancer: A tissue microarray study on 179 urothelial carcinomas from cystectomy specimens

Pathology

Volumn 42, Issue 1, 2010, Pages 37-42

  Karamitopoulou, Eva ^a   Rentsch, Cyrill A ^b   Markwalder, Regula ^c   Vallan, Claudio ^c   Thalmann, George N ^b   Brunner, Thomas ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Active caspase 3; Apoptosis; Bladder cancer; SsDNA

Indexed keywords

EID: 73649099478     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313020903434397     Document Type: Article

References (27)

1. Baithun SI, Naase M, Blanes A, Diaz-Cano SJ. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch 2001; 438289-438297
2. Lipponen PK, Aaltoma S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 173: 333-339
3. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM. P53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 1994; 25: 1346-1351 (Pubitemid 24378743)
4. McKnight JJ, Gray SB, O'Kane HF, Johnston SR, Williamson KE. Apoptosis and chemotherapy for bladder cancer. J Urol 2005; 173: 683-690
5. Tabassum A, Khwaja F, Djakiew D. The p75 (NTR) tumor suppressor induces caspase-mediated apoptosis on bladder tumor cells. Int J Cancer 2003; 105: 47.
6. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-1430
7. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12: 1551-1570
8. Thornberry N, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316
9. Slee EA, Adrain C, Martin SJ. Executioner caspase-3,-6, and-7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320-7326
10. Duan WR, Garner DS, Williams SD, et al. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantitation of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 2003; 199: 221-228
11. Korkolopoulou P, Konstantinidou AE, Christodoulou P, et al. Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival. Urology 2000; 56: 516-520
12. Sobin LH, Wittekind C. International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss, 2002.
13. Lopez-Beltran A, Sauter G, Gasser T. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2002; Infiltrating urothelial carcinoma.
14. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001; 159: 2249-2256
15. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU International 2005; 96: 7-12.
16. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: International consensus panel on bladder tumor markers. Urology 2005; 66(Suppl 6A): 64-74. (Pubitemid 43049609)
17. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-348
18. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med 2000; 343: 1418-1420
19. Juin P, Hunt A, Littlewood T, et al. C-myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol 2002; 22: 6158-6169
20. Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-136
21. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNAse that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
22. Chowdhury I, Tharakan B, Bhat GK. Current concepts in apoptosis: The physiological suicide program revisited. Cell Mol Biol Lett 2006; 11: 506-525
23. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259-1264
24. Schmitz-Dräger BJ, Goebell PJ, Ebert T, et al. P53 immunohistochemistry as a prognosis marker in bladder cancer. Playground for urology scientists? Eur Urol 2000; 38: 691-699
25. Glick SH, Howell LP, Devere White RW. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 1996; 155: 1754-1757
26. Smith WL, Marnett LJ, DeWitt DL. Prostanglandin and thromboxane biosynthesis. Pharmacol Ther 1991; 49: 153-179
27. Shirahama T, Arima J, Akiba S. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001; 92: 188-193